2D and 3D Cellular Screening Models and AI Guided Analysis, Volume 204 explores the development, application, and comparative benefits of 2D monolayer cultures and 3D organoids, spheroids, and tissue-engineered constructs for biomedical research and drug discovery. Chapters in this new release include High throughput CellTiter-glo viability assessment, Assessing viability of cancer cell spheroids in 3D drug screening, 3D killing assay of cancer spheroids by cytotoxic T lymphocytes in anchored microfluidic droplets, Use of micropatterning for 3D cell culture, Use of microfluidic chip devices for assessing the effect of radiation on 3D cell culture models, and much more.
Additional chapters cover A 3D model for assessing regulated cell death modalities, YOLO detection model for Cell Viability assessment, Bioinformatics and AI/ML approaches using multi-omics data to accelerate diagnosis and delivery of precision care, Automated image analysis and machine learning for the assessment of mitochondrial membrane potential, Assessing cancer cell heterogeneity in patient-derived tumoroids, Assessment of lysosomal drug sequestration and release using fluorescence microscopy, Assessment of T cell toxicity in ex-vivo models of cancer, Three-dimensional Organoid Screening using Leica Thunder Microscope, Using vascularized organoids-on-chip for assessing systemic drug delivery, and many more interesting and timely topics.
1. Preface
Guido Kroemer and Oliver Kepp
2. High throughput CellTiter-glo viability assessment
Dana Alawieh and Aline Renneville
3. Assessing viability of cancer cell spheroids in 3D drug screening
Oliver Kepp and Marion Leduc
4. 3D killing assay of cancer spheroids by cytotoxic T lymphocytes in
anchored microfluidic droplets
Charles Baroud
5. Use of micropatterning for 3D cell culture
Emna Ouni and Kristine Schauer
6. Use of microfluidic chip devices for assessing the effect of radiation on
3D cell culture models
Philip Wong, Rodin Chermat, Elena Refet-Mollof, Maryam Ziaee, Julie
Lafontaine and Thomas Gervais
7. A 3D model for assessing regulated cell death modalities
Dmitri Krysko and Robin Demuynck
8. YOLO detection model for Cell Viability assessment
Felix Peyre
9. Bioinformatics and AI/ML approaches using multi-omics data to accelerate
diagnosis and delivery of precision care
Zeeshan Ahmed, Kritika Singh, Sarah Usman, Saman Zeeshan, Naveena Yanamala,
Vikram Bhise, Mark Nichols, Sabahat Bokhari and Partho Sengupta
10. Automated image analysis and machine learning for the assessment of
mitochondrial membrane potential
Marta Giacomello, Camilla Bean, Federica Dal bello, Emad Norouzi Esfahani,
Alessio Gianelle, Saradha Ramesh, Luca Persano, Elena Rampazzo and Caterina
Vianello
11. Assessing cancer cell heterogeneity in patient-derived tumoroids
Flora Doffe
12. Assessment of lysosomal drug sequestration and release using fluorescence
microscopy
Karla Alvarez, Mojgan Djavaheri-Mergny, Guido Kroemer, Lucille Ferret, Samy
Dehissi and Jean Guillon
13. Assessment of T cell toxicity in ex-vivo models of cancer
Emmanuel intégrative des tumeurs et immunothérapie Donnadieu and Alice
Machado
14. Three-dimensional Organoid Screening using Leica Thunder Microscope
Manoliu Tudor
15. Using vascularized organoids-on-chip for assessing systemic drug
delivery
Xavier Gidrol, Emily Tubbs, Fabrice P Navarro and Yves Fouillet
16. Quantitative assessment of nanoparticle uptake and trafficking in 3D cell
culture models
Meritxell B. Cutrona
17. Fluorescence microscopic quantitation of lysosomal cholesterol
accumulation induced by cationic amphiphilic drugs
Mojgan Djavaheri-Mergny, Karla Alvarez, Samy Dehissi, Lucille Ferret and
Guido Kroemer
Lorenzo Galluzzi is Assistant Professor of Cell Biology in Radiation Oncology at the Department of Radiation Oncology of the Weill Cornell Medical College, Honorary Assistant Professor Adjunct with the Department of Dermatology of the Yale School of Medicine, Honorary Associate Professor with the Faculty of Medicine of the University of Paris, and Faculty Member with the Graduate School of Biomedical Sciences and Biotechnology of the University of Ferrara, the Graduate School of Pharmacological Sciences of the University of Padova, and the Graduate School of Network Oncology and Precision Medicine of the University of Rome La Sapienza”. Moreover, he is Associate Director of the European Academy for Tumor Immunology and Founding Member of the European Research Institute for Integrated Cellular Pathology.
Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. He has published over 450 articles in international peer-reviewed journals and is the Editor-in-Chief of four journals: OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, Methods in Cell biology, and Molecular and Cellular Oncology (which he co-founded in 2013). Additionally, he serves as Founding Editor for Microbial Cell and Cell Stress, and Associate Editor for Cell Death and Disease, Pharmacological Research and iScience. Dr. Oliver Kepp graduated from Humboldt University Berlin and obtained a PhD degree in Molecular Biology. Today he is a tenured researcher at INSERM and a Co-director of the BioCell automation platform at GRCC. Oliver and his team investigate several aspects of tumor immunogenicity, focusing on systems cell biology approaches. He is also a co-founder of Samsara therapeutics and was appointed associate director of the European academy of tumor immunology in 2019. Oliver received the prestigious Clarivate Highly Cited Researcher Award four years in a row since 2018 and has recently been ranked among the top biology and biochemistry scientists in France (#5; www.research.com) Guido Kroemer got his M.D. in 1985 from the University of Innsbruck, Austria, and his Ph.D. in molecular biology in 1992 from the Autonomous University of Madrid, Spain. He is currently Professor at the Faculty of Medicine of the University of Paris Descartes/Paris V, Director of the INSERM research team Apoptosis, Cancer and Immunity, Director of the Metabolomics and Cell Biology platforms of the Gustave Roussy Cancer Campus, and Practitioner at the Hôpital Européen George Pompidou (Paris, France). He is also the Director of the Paris Alliance of Cancer Research Institutes (PACRI) and the Labex 'Immuno-Oncology'. Dr. Kroemer is best known for the discoveries that mitochondrial membrane permeabilization constitutes a decisive step in regulated cell death; that autophagy is a cytoprotective mechanism with lifespan-extending effects; and that anticancer therapies are successful only if they stimulate tumour-targeting immune responses. He is currently the most-cited cell biologist in Europe (relative to the period 2007-2013), and he has received the Descartes Prize of the European Union, the Carus Medal of the Leopoldina, the Dautrebande Prize of the Belgian Royal Academy of Medicine, the Léopold Griffuel Prize of the French Association for Cancer Research, the Mitjavile prize of the French National Academy of Medicine and a European Research Council Advanced Investigator Award.
